Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A. Generali D, et al. Among authors: bersiga a. Clin Cancer Res. 2008 May 1;14(9):2673-80. doi: 10.1158/1078-0432.CCR-07-1046. Clin Cancer Res. 2008. PMID: 18451231 Clinical Trial.
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A. Bottini A, et al. Among authors: bersiga a. J Clin Oncol. 2006 Aug 1;24(22):3623-8. doi: 10.1200/JCO.2005.04.5773. J Clin Oncol. 2006. PMID: 16877730 Free article. Clinical Trial.
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB. Generali D, et al. Among authors: bersiga a. Clin Cancer Res. 2006 Aug 1;12(15):4562-8. doi: 10.1158/1078-0432.CCR-05-2690. Clin Cancer Res. 2006. PMID: 16899602 Free article. Clinical Trial.
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL. Generali D, et al. Among authors: bersiga a. Endocr Relat Cancer. 2006 Sep;13(3):921-30. doi: 10.1677/erc.1.01216. Endocr Relat Cancer. 2006. PMID: 16954440
Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
Generali D, Fox SB, Berruti A, Moore JW, Brizzi MP, Patel N, Allevi G, Bonardi S, Aguggini S, Bersiga A, Campo L, Dogliotti L, Bottini A, Harris AL. Generali D, et al. Among authors: bersiga a. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):550-8. doi: 10.1158/1078-0432.CCR-06-1266. Clin Cancer Res. 2007. PMID: 17255277 Clinical Trial.
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB. Generali D, et al. Among authors: bersiga a. J Clin Oncol. 2009 Jan 10;27(2):227-34. doi: 10.1200/JCO.2007.13.7083. Epub 2008 Dec 8. J Clin Oncol. 2009. PMID: 19064988 Free article. Clinical Trial.
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, Milani M, Allevi G, Bonardi S, Aguggini S, Volante M, Dogliotti L, Bottini A, Harris A, Berruti A. Mele T, et al. Among authors: bersiga a. Breast Cancer Res Treat. 2010 Oct;123(3):795-804. doi: 10.1007/s10549-010-1063-0. Epub 2010 Aug 3. Breast Cancer Res Treat. 2010. PMID: 20680681 Clinical Trial.
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
Fox SB, Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Mele T, Dogliotti L, Bottini A, Harris AL. Fox SB, et al. Among authors: bersiga a. Breast Cancer Res. 2011 Feb 3;13(1):R16. doi: 10.1186/bcr2825. Breast Cancer Res. 2011. PMID: 21291529 Free PMC article. Clinical Trial.
35 results